Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
12 April 2023 - 2:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a
biopharmaceutical company focused on discovering and developing
potential best-in-class medicines for serious and rare diseases,
today announced the appointment of Tony Casciano to the role of
Chief Commercial Officer (CCO). The Company also announced that
Chief Operating Officer (COO) Carrie Melvin is no longer with the
organization.
Mr. Casciano, who most recently served as Chief Executive
Officer (CEO) and member of the board of directors of Teal Bio,
brings to Viridian more than two decades of sales, marketing, and
commercial leadership experience in the biopharma industry.
“Tony’s arrival marks an important milestone in Viridian’s
growth and maturation,” said Scott Myers, President and CEO of
Viridian. “With the lead asset in our thyroid eye disease (TED)
program in a Phase 3 trial and additional investigational therapies
for TED following close behind, it is imperative that we focus on
building a world class commercial operation. I’m confident that
under Tony’s seasoned leadership, we’ll be well positioned to do
just that. I’m thrilled to be working with him in this endeavor as
we pursue our vision to become a fully integrated biopharmaceutical
company.”
Prior to leading Teal Bio, Mr. Casciano spent four years at AMAG
Pharmaceuticals, serving initially as Senior Vice President, Head
of U.S. Sales and Marketing before ascending to Executive Vice
President, COO/CCO. During his time at AMAG, he was responsible for
leading more than 300 staff across a range of functions, including
commercial, market access, patient services, and alliance
management.
“I’m delighted to be joining Viridian at such a remarkable time
for the organization,” said Mr. Casciano. “Throughout my career,
I’ve taken immense pride in assembling high-performing teams to
help ensure that patients gain access to the therapies they need.
It’s incredibly exciting to think that Viridian is moving closer to
delivering novel therapies to an underserved population, and I’m
honored to be able to play an important part in that process.”
Mr. Casciano began his career in industry in sales positions at
Sanofi/Genzyme, rising through that organization in roles of
increasing responsibility. He completed his 16-year tenure there as
Head of Marketing, General Medicines. He holds a B.S. from
Bridgewater State University and has completed multiple executive
education programs.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on
engineering and developing potential best-in-class medicines for
patients with serious and rare diseases. Viridian’s expertise in
antibody discovery and engineering enables it to develop
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
recently initiated its first global Phase 3 trial called ‘THRIVE’
to evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also evaluating VRDN-001 in a Phase 2
proof-of-concept trial in patients with chronic TED. In addition to
its intravenously administered VRDN-001 program, the Company is
advancing two candidates for its subcutaneous strategy with the
goal of providing a more conveniently administered therapy to
patients with TED. Viridian is developing multiple preclinical
assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and twitter.
ContactsInvestors:Louisa Stone,
508-808-2400Manager, Investor
RelationsIR@viridiantherapeutics.com
Todd James, 617-272-4691Senior Vice President, Corporate Affairs
and Investor RelationsIR@viridiantherapeutics.com
Media:Matt Fearer, 617-272-4605Vice President, Corporate
CommunicationsMedia@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024